Published in J Matern Fetal Neonatal Med on August 25, 2011
Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): study protocol. BMC Pregnancy Childbirth (2014) 0.89
Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol (2015) 0.88
Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death. Am J Obstet Gynecol (2013) 0.87
Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Matern Fetal Neonatal Med (2013) 0.87
Decidual Cox2 inhibition improves fetal and maternal outcomes in a preeclampsia-like mouse model. JCI Insight (2016) 0.85
Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD). J Matern Fetal Neonatal Med (2015) 0.85
The impact of resilience on psychological outcomes in women after preeclampsia: an observational cohort study. Health Qual Life Outcomes (2013) 0.84
Preeclampsia, of mice and women. Physiol Genomics (2016) 0.82
Role of decidual natural killer cells, interleukin-15, and interferon-γ in placental development and preeclampsia. Am J Physiol Regul Integr Comp Physiol (2014) 0.81
Systematic Review of Micro-RNA Expression in Pre-Eclampsia Identifies a Number of Common Pathways Associated with the Disease. PLoS One (2016) 0.79
Potential role of A2B adenosine receptors on proliferation/migration of fetal endothelium derived from preeclamptic pregnancies. Biomed Res Int (2014) 0.79
Placental disease and the maternal syndrome of preeclampsia: missing links? Curr Hypertens Rep (2013) 0.79
Placental lesions associated with acute atherosis. J Matern Fetal Neonatal Med (2014) 0.77
Biomarker development for presymptomatic molecular diagnosis of preeclampsia: feasible, useful or even unnecessary? Expert Rev Mol Diagn (2015) 0.77
FLT1 and transcriptome-wide polyadenylation site (PAS) analysis in preeclampsia. Sci Rep (2017) 0.76
Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy. BMC Pregnancy Childbirth (2014) 0.76
Increased Risk of Intracranial Hemorrhage in Patients With Pregnancy-Induced Hypertension: A Nationwide Population-Based Retrospective Cohort Study. Medicine (Baltimore) (2016) 0.76
Prenatal diagnosis of a placental infarction hematoma associated with fetal growth restriction, preeclampsia and fetal death: clinicopathological correlation. Fetal Diagn Ther (2014) 0.75
Placental growth factor: as an early second trimester predictive marker for preeclampsia in normal and high-risk pregnancies in a Turkish population. J Obstet Gynaecol India (2012) 0.75
Increased risk of systemic lupus erythematosus in pregnancy-induced hypertension: A nationwide population-based retrospective cohort study. Medicine (Baltimore) (2016) 0.75
Maternal plasma soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia - a longitudinal study. J Matern Fetal Neonatal Med (2017) 0.75
The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study. PLoS One (2017) 0.75
WHO analysis of causes of maternal death: a systematic review. Lancet (2006) 20.24
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
A United States national reference for fetal growth. Obstet Gynecol (1996) 13.21
Latest advances in understanding preeclampsia. Science (2005) 8.11
ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol (2002) 7.40
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol (1989) 5.73
Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol (1999) 4.74
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol (1998) 3.37
Rise in maternal mortality in the Netherlands. BJOG (2009) 3.15
Preeclampsia: recent insights. Hypertension (2005) 2.98
Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int (2007) 2.87
Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology (2004) 2.83
The two stage model of preeclampsia: variations on the theme. Placenta (2008) 2.78
Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension (2007) 2.77
Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol (1997) 2.66
Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol (2011) 2.66
Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension (2007) 2.53
Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res (2004) 2.52
Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol (1997) 2.46
Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension (2008) 2.42
Preeclampsia and fetal growth. Obstet Gynecol (2000) 2.38
Subclassification of preeclampsia. Hypertens Pregnancy (2003) 2.25
Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol (2001) 2.22
Immunology of pre-eclampsia. Am J Reprod Immunol (2010) 2.22
Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol (2009) 2.12
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) (2009) 2.10
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol (2005) 2.03
Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group. Obstet Gynecol (2000) 1.99
The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol (2010) 1.99
Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med (2005) 1.99
Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol (1991) 1.91
Development of the placental villous tree and its consequences for fetal growth. Eur J Obstet Gynecol Reprod Biol (2000) 1.87
A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med (2009) 1.84
Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol (2004) 1.81
Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol (1998) 1.79
Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res (2005) 1.78
Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension (2005) 1.74
Overview of maternal morbidity during hospitalization for labor and delivery in the United States: 1993-1997 and 2001-2005. Obstet Gynecol (2009) 1.72
Maternal vascular underperfusion: nosology and reproducibility of placental reaction patterns. Pediatr Dev Pathol (2004) 1.70
Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta (2005) 1.62
The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med (2008) 1.60
Placental diagnostic criteria and clinical correlation--a workshop report. Placenta (2005) 1.53
The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med (2008) 1.50
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn (2011) 1.48
Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension (2005) 1.48
Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol (2007) 1.47
Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension (2008) 1.45
Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol (2001) 1.42
Is pre-eclampsia more than one disease? BJOG (2004) 1.42
The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol (2003) 1.41
Role of reactive oxygen species in hypertension produced by reduced uterine perfusion in pregnant rats. Am J Hypertens (2008) 1.38
Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol (2010) 1.37
Intrauterine growth restriction with absent end-diastolic flow velocity in the umbilical artery is associated with maldevelopment of the placental terminal villous tree. Am J Obstet Gynecol (1996) 1.35
Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol (2007) 1.34
Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol (2006) 1.32
Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. BJOG (2006) 1.30
Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta (1997) 1.29
Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol (2007) 1.28
Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol (2006) 1.28
Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol (2008) 1.26
Toll-like receptor 4: a potential link between "danger signals," the innate immune system, and preeclampsia? Am J Obstet Gynecol (2005) 1.26
Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One (2010) 1.25
Hypertension in response to AT1-AA: role of reactive oxygen species in pregnancy-induced hypertension. Am J Hypertens (2011) 1.24
Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol (2001) 1.23
Taking tissue samples from the placenta: an illustration of principles and strategies. Placenta (2007) 1.20
Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol (2007) 1.20
Activation of leukocytes during the uteroplacental passage in preeclampsia. Hypertension (2002) 1.17
Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol (2008) 1.17
Role of placenta in preeclampsia. Endocrine (2002) 1.16
Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol (2006) 1.16
Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta (2003) 1.16
Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol (2008) 1.14
Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension (2007) 1.13
The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro. Placenta (2008) 1.13
Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol (2003) 1.12
Apoptosis cascade progresses during turnover of human trophoblast: analysis of villous cytotrophoblast and syncytial fragments in vitro. Lab Invest (1999) 1.12
Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am (2010) 1.11
Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol (2008) 1.10
Emerging roles of antiangiogenic and angiogenic proteins in pathogenesis and prediction of preeclampsia. Hypertension (2007) 1.09
Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol (2008) 1.09
Expression of vascular endothelial growth factor, placental growth factor, and their receptors Flt-1 and KDR in human placenta under pathologic conditions. Hum Pathol (2002) 1.08
Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta (2010) 1.08
First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol (2008) 1.08
Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Matern Fetal Med (1999) 1.07
Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol (2006) 1.07
Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia. J Matern Fetal Neonatal Med (2002) 1.07
Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res (2007) 1.06
An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. Am J Obstet Gynecol (2005) 1.05
Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand (2008) 1.04
Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest (2003) 1.04
Evidence of in vivo generation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia. J Matern Fetal Neonatal Med (2002) 1.04
Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab (2005) 1.02
Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. J Perinat Med (2011) 1.01
The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG (2010) 1.01
Epidemiology and causes of preterm birth. Lancet (2008) 18.96
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
A systems biology approach for pathway level analysis. Genome Res (2007) 6.95
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
A novel signaling pathway impact analysis. Bioinformatics (2008) 5.06
The role of inflammation and infection in preterm birth. Semin Reprod Med (2007) 3.57
Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med (2012) 3.43
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. PLoS One (2008) 3.01
Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol (2011) 2.95
Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. Lancet (2008) 2.90
Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol (2007) 2.78
Inflammation in preterm and term labour and delivery. Semin Fetal Neonatal Med (2006) 2.59
Machine learning and its applications to biology. PLoS Comput Biol (2007) 2.57
Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. Am J Obstet Gynecol (2003) 2.55
Intrauterine infection and prematurity. Ment Retard Dev Disabil Res Rev (2002) 2.42
The fetal inflammatory response syndrome. Clin Obstet Gynecol (2007) 2.36
The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non-pregnant women. Microbiome (2014) 2.24
Listeriosis in human pregnancy: a systematic review. J Perinat Med (2011) 2.20
The role of cervical cerclage in obstetric practice: can the patient who could benefit from this procedure be identified? Am J Obstet Gynecol (2006) 2.11
Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury. Nutr Rev (2007) 2.01
The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol (2010) 1.99
Leukodystrophy in children: a pictorial review of MR imaging features. Radiographics (2002) 1.99
Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med (2005) 1.99
Evolution of the mammalian placenta revealed by phylogenetic analysis. Proc Natl Acad Sci U S A (2006) 1.89
Genomics, biogeography, and the diversification of placental mammals. Proc Natl Acad Sci U S A (2007) 1.86
A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med (2009) 1.84
A sonographic short cervix as the only clinical manifestation of intra-amniotic infection. J Perinat Med (2006) 1.82
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res (2002) 1.82
Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol (2004) 1.81
Infection and prematurity and the role of preventive strategies. Semin Neonatol (2002) 1.78
Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery. J Matern Fetal Neonatal Med (2010) 1.77
Universal cervical length screening and treatment with vaginal progesterone to prevent preterm birth: a decision and economic analysis. Am J Obstet Gynecol (2010) 1.77
Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. Am J Obstet Gynecol (2009) 1.77
Identification of fetal and maternal single nucleotide polymorphisms in candidate genes that predispose to spontaneous preterm labor with intact membranes. Am J Obstet Gynecol (2010) 1.75
Prevalence and diversity of microbes in the amniotic fluid, the fetal inflammatory response, and pregnancy outcome in women with preterm pre-labor rupture of membranes. Am J Reprod Immunol (2010) 1.74
Human spontaneous labor without histologic chorioamnionitis is characterized by an acute inflammation gene expression signature. Am J Obstet Gynecol (2006) 1.73
Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol (2011) 1.69
Gene-centric genomewide association study via entropy. Genetics (2008) 1.68
Nifedipine in the management of preterm labor: a systematic review and metaanalysis. Am J Obstet Gynecol (2011) 1.65
Divergent trophoblast responses to bacterial products mediated by TLRs. J Immunol (2004) 1.64
A short cervix in women with preterm labor and intact membranes: a risk factor for microbial invasion of the amniotic cavity. Am J Obstet Gynecol (2005) 1.64
Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway. Cancer Res (2002) 1.64
Antibiotic administration to patients with preterm premature rupture of membranes does not eradicate intra-amniotic infection. J Matern Fetal Neonatal Med (2007) 1.62
The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med (2008) 1.60
Clinical significance of intra-amniotic inflammation in patients with preterm premature rupture of membranes. Am J Obstet Gynecol (2004) 1.60
Intrauterine endotoxin administration leads to white matter diffusivity changes in newborn rabbits. J Child Neurol (2009) 1.58
Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. Am J Obstet Gynecol (2002) 1.58
Structural and functional comparison of mast cells in the pregnant versus nonpregnant human uterus. Am J Obstet Gynecol (2006) 1.54
The clinical significance of a positive Amnisure test in women with term labor with intact membranes. J Matern Fetal Neonatal Med (2009) 1.54
A systematic approach to the use of the multiplanar display in evaluation of abnormal vascular connections to the fetal heart using 4-dimensional ultrasonography. J Ultrasound Med (2007) 1.53
Analysis of microarray experiments of gene expression profiling. Am J Obstet Gynecol (2006) 1.53
The ninety-fifth percentile for growth discordance predicts complications of twin pregnancy. Am J Obstet Gynecol (2002) 1.53
Macrophages and apoptotic cell clearance during pregnancy. Am J Reprod Immunol (2004) 1.51
Amniotic fluid embolism: an evidence-based review. Am J Obstet Gynecol (2009) 1.50
The evolution of menstruation: a new model for genetic assimilation: explaining molecular origins of maternal responses to fetal invasiveness. Bioessays (2011) 1.50
The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med (2008) 1.50
Toll-like receptor-2 and -4 in the chorioamniotic membranes in spontaneous labor at term and in preterm parturition that are associated with chorioamnionitis. Am J Obstet Gynecol (2004) 1.49
A randomized trial of amnioreduction versus septostomy in the treatment of twin-twin transfusion syndrome. Am J Obstet Gynecol (2005) 1.48
The prognosis of pregnancy conceived despite the presence of an intrauterine device (IUD). J Perinat Med (2010) 1.48